On October 9, 2023 InCephalo AG reported the company , University of Basel and VitroScan receive a competitive Eurostars grant (€2.3M) to accelerate the development of promising new drugs for Glioblastoma patients – CLEIO (Press release, InCephalo Therapeutics, OCT 9, 2023, View Source [SID1234644133]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The consortium led by InCephalo AG has received the competitive Eurostar grant. The Swiss – Dutch consortium consist of three collaborating partners: InCephalo AG, University of Basel and VitroScan.
In the CLEIO project: The first-in-kind Compartment Locked and Effective ImmunOtherapy against glioblastoma, the consortium will: i) study the effect of InC01 (InCephalo’s primary asset) treatment on established ex- vivo GBM models based on patient tissue, ii) discover new biomarkers for the response and non-response of InC01, and iii) drive clinical Phase II trial design through stratification of patient populations.
«We are excited to receive this grant as will allow us to de-risk our
clinical development at such an early stage» says Dr. Carlo Bertozzi,
CEO and co-founder of InCephalo.
Willemijn Vader, CEO VitroScan:
«It is a great opportunity for VitroScan to collaborate with these partners and integrate our expertise to develop predictive tools for new novel treatment options for glioblastoma patients».
Prof. G. Hutter, Neurosurgeon and Group leader at both the Unversity of Basel and the University Hospital in Basel:
«As a treating physician, I see that novel therapeutic modalities are needed for brain cancer patients. In this collaboration, we are actively working to push InC01, a promising new modality, closer to the patient and on the way learn more about which patients are more likely to react».